Kogevinas Manolis, Karachaliou Marianna, Espinosa Ana, Iraola-Guzmán Susana, Castaño-Vinyals Gemma, Delgado-Ortiz Laura, Farré Xavier, Blay Natàlia, Pearce Neil, Bosch de Basea Magda, Nogués Eva Alonso, Dobaño Carlota, Moncunill Gemma, de Cid Rafael, Garcia-Aymerich Judith
ISGlobal, Barcelona, Spain.
CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
BMC Med. 2025 Mar 14;23(1):140. doi: 10.1186/s12916-025-03974-7.
Long-COVID has mostly been investigated in clinical settings. We aimed to assess the risk, subtypes, persistence, and determinants of long-COVID in a prospective population-based study of adults with a history of SARS-CoV-2 infection in Catalonia.
We examined 2764 infected individuals from a population-based cohort (COVICAT) established before the pandemic and followed up three times across the pandemic (2020, 2021, 2023). We assessed immunoglobulin (Ig)G levels against SARS-CoV-2, clinical, vaccination, sociodemographic, and lifestyle factors. Long-COVID risk and subtypes were defined based on participant-reported symptoms and electronic health records. We identified a total of 647 long-COVID cases and compared them with 2117 infected individuals without the condition.
Between 2021 and 2023, 23% of infected subjects developed long-COVID symptoms. In 56% of long-COVID cases in 2021, symptoms persisted for 2 years. Long-COVID presented clinically in three subtypes, mild neuromuscular, mild respiratory, and severe multi-organ. The latter was associated with persistent long-COVID. Risk was higher among females, participants under 50 years, of low socioeconomic status, severe COVID-19 infection, elevated pre-vaccination IgG levels, obesity, and prior chronic disease, particularly asthma/chronic obstructive pulmonary disease and mental health conditions. A lower risk was associated to pre-infection vaccination, infection after omicron became the dominant variant, higher physical activity levels, and sleeping 6-8 h. Vaccination during the 3 months post-infection was also protective against long-COVID.
Long-COVID persisted for up to 2 years in half of the cases, and risk was influenced by multiple factors.
长期新冠大多在临床环境中进行研究。我们旨在通过一项针对加泰罗尼亚有SARS-CoV-2感染史成年人的前瞻性人群研究,评估长期新冠的风险、亚型、持续时间及决定因素。
我们对大流行前建立的基于人群的队列(COVICAT)中的2764名感染者进行了检查,并在整个大流行期间(2020年、2021年、2023年)进行了三次随访。我们评估了针对SARS-CoV-2的免疫球蛋白(Ig)G水平、临床、疫苗接种、社会人口统计学和生活方式因素。长期新冠的风险和亚型根据参与者报告的症状和电子健康记录来定义。我们共识别出647例长期新冠病例,并将其与2117名未患此病的感染者进行比较。
在2021年至2023年期间,23%的感染者出现了长期新冠症状。2021年56%的长期新冠病例症状持续了两年。长期新冠临床上表现为三种亚型,轻度神经肌肉型、轻度呼吸型和重度多器官型。后者与持续性长期新冠相关。女性、50岁以下参与者、社会经济地位低、严重新冠病毒感染、接种疫苗前IgG水平升高、肥胖以及既往慢性病,尤其是哮喘/慢性阻塞性肺疾病和心理健康状况者,风险更高。感染前接种疫苗、在奥密克戎成为主要变异株后感染、较高的身体活动水平以及睡眠6 - 8小时与较低风险相关。感染后3个月内接种疫苗也可预防长期新冠。
半数病例中,长期新冠症状持续长达两年,且风险受多种因素影响。